Skip to main content

Table 1 Clinicopathologic characteristics of patients

From: A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

  Overall Training set Validation set
ALL (N) pCR (N) pCR rate ALL (N) pCR (N) pCR rate ALL (N) pCR (N) pCR rate
Total 815 111 13.6 % 500 68 13.6 % 315 43 13.7 %
Age
 ≤40 years 165 28 17.0 % 105 17 16.2 % 60 11 18.3 %
 >40 years 650 83 12.8 % 395 51 12.9 % 255 32 12.5 %
Menopausal status
 Pre-menopausal 457 65 14.2 % 276 40 14.5 % 181 25 13.8 %
 Post-menopausal 358 46 12.8 % 224 28 12.5 % 134 18 13.4 %
Tumor size
 T1 89 21 23.6 % 60 15 25.0 % 29 6 20.7 %
 T2 346 47 13.6 % 210 30 14.3 % 136 17 12.5 %
 T3 235 28 11.9 % 137 15 10.9 % 98 13 13.3 %
 T4 145 15 10.3 % 93 8 8.6 % 52 7 13.5 %
Nodal status
 N0 170 22 12.9 % 100 15 15.0 % 70 7 10.0 %
 N1 593 79 13.3 % 363 45 12.4 % 230 34 14.8 %
 N2 23 4 17.4 % 16 3 18.8 % 7 1 14.3 %
 N3 29 6 20.7 % 21 5 23.8 % 8 1 12.5 %
Hormone receptor status
 Negative 235 54 23.0 % 147 36 24.5 % 88 18 20.5 %
 Positive 580 57 9.8 % 353 32 9.1 % 227 25 11.0 %
Regimens
 Cyclophosphamide, epirubicin and 5-fluorouracil 107 2 1.9 % 66 1 1.5 % 41 1 2.4 %
 Cyclophosphamide, epirubicin and 5-fluorouracil followed by paclitaxel or docetaxel and epirubicin 116 9 7.8 % 73 5 6.8 % 43 4 9.3 %
 Navelbine and epirubicin 153 15 9.8 % 94 8 8.5 % 59 7 11.9 %
 Paclitaxel and carboplatin or paclitaxel and cisplatin 439 85 19.4 % 267 54 20.2 % 172 31 18.0 %
Cycles
 1-2 97 3 3.1 % 61 2 3.3 % 36 1 2.8 %
 3-4 578 93 16.1 % 359 58 16.2 % 219 35 16.0 %
 5-6 140 15 10.7 % 80 8 10.0 % 60 7 11.7 %
  1. Abbreviations: pCR pathological complete response